New combo therapy hopes to slow ALS progression

NCT ID NCT07414212

Recruiting now Disease control Sponsor: Biogipuzkoa Health Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking N-acetylcysteine (NAC) and EH-301 together with the standard drug riluzole can slow down amyotrophic lateral sclerosis (ALS). About 90 people with early-stage ALS will receive either the active combination or a placebo for 6 months. After that, everyone can receive the active treatment for another 6 months. The main goal is to see if the combination helps maintain daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-acetylcysteine (NAC) and EH-301 (nicotinamide riboside and pterostilbene) taken together with riluzole
What this could lead to: If it works, this combination could slow down ALS progression and help maintain daily function for longer.
What could go wrong: This is an early-phase trial with only 90 participants, so results may not apply to all ALS patients. The treatment may not slow the disease or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Hospital Universitario Donostia
RECRUITING

San Sebastián, Guipuzcoa, 20003, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.